SCHEMBL29308017

SCHEMBL29308017

CC(C)C[C@@H](NC(=O)OCc1ccccc1)C(=O)N[C@@H](C)C(=O)O

nearest known ligand 0.78

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CAPN1 P07384 2/20 0.78
CTSK P43235 11/20 0.75
CTSL P07711 5/20 0.70
CTSS P25774 3/20 0.70
CTSB P07858 3/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8823914 1.00 CAPN1 (0.78) CAPN1CTSKCTSLCTSSCTSB
SCHEMBL9338295 1.00 CAPN1 (0.78) CAPN1CTSKCTSLCTSSCTSB
SCHEMBL2471949 1.00 CAPN1 (0.78) CAPN1CTSKCTSLCTSSCTSB
SCHEMBL8584264 0.95 CAPN1 (0.72) CAPN1CTSKCTSLCTSSCTSB
SCHEMBL8585293 0.95 CAPN1 (0.72) CAPN1CTSKCTSLCTSSCTSB
SCHEMBL8585289 0.93 CAPN1 (0.69) CAPN1CTSKCTSLCTSSCTSB
SCHEMBL8584262 0.93 CAPN1 (0.69) CAPN1CTSKCTSLCTSSCTSB
SCHEMBL7612532 0.91 CTSK (0.71) CAPN1CTSKCTSLCTSSCTSB
SCHEMBL7612544 0.91 CTSK (0.71) CAPN1CTSKCTSLCTSSCTSB
SCHEMBL8823936 0.91 CAPN1 (0.78) CAPN1CTSKCTSLCTSSCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240366779-A1 SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS SEAGEN INC (US) 2024-11-07 US disclosed
US-12036286-B2 Selective drug release from internalized conjugates of biologically active compounds SEAGEN INC. (US) 2024-07-16 US disclosed
US-12036286-B2 Selective drug release from internalized conjugates of biologically active compounds SEAGEN INC. (US) 2024-07-16 US disclosed
US-20240207427-A1 SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS SEAGEN INC (US) 2024-06-27 US disclosed
EP-4308170-A1 SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS Seagen Inc. (US) 2024-01-24 EP disclosed
EP-4308171-A1 SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS Seagen Inc. (US) 2024-01-24 EP disclosed
CN-117120097-A Selective drug release of internalized bioactive compound conjugates 思进公司 2023-11-24 CN disclosed
US-20230091653-A1 SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS SEAGEN INC. 2023-03-23 US disclosed
WO-2022198231-A1 SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS SEAGEN INC. (US) 2022-09-22 WO disclosed
WO-2022198232-A1 SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS SEAGEN INC. (US) 2022-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240207427-A1 SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS CTSB, CTSE, CTSZ CAPN1 232/4885CTSK 11/4885CTSL 14/4885
US-20240366779-A1 SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS CTSB, CTSE, CTSZ CAPN1 232/4885CTSK 11/4885CTSL 14/4885
US-12036286-B2 Selective drug release from internalized conjugates of biologically active compounds CTSB, CTSE, CTSZ CAPN1 232/4885CTSK 11/4885CTSL 14/4885
US-20230091653-A1 SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS CTSB, CTSE, CTSZ CAPN1 232/4885CTSK 11/4885CTSL 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.